175 filings
Page 8 of 9
8-K
xn19ws07xsa5zpoybwh
2 Nov 04
Amylin Pharmaceuticals Reports Third Quarter Financial Results
12:00am
8-K
t3soz1 1ecza25l
13 Oct 04
Entry into a Material Definitive Agreement
12:00am
8-K
nqijbtn 8ixw52z
20 Sep 04
Other Events
12:00am
8-K
i0wajynk9s
1 Sep 04
Other Events
12:00am
8-K
wzhew qrm0dq24sddd
5 Aug 04
Amylin Pharmaceuticals Reports Second Quarter Financial Results
12:00am
8-K
c0xrpdi bsb1j
23 Jul 04
Current report
12:00am
8-K
3urony7
30 Jun 04
New Drug Application for Exenatide Submitted to FDA for Type 2 Diabetes
12:00am
8-K
drfa9xcku723
8 Jun 04
Data From Pivotal Studies to Form the Basis of a Mid-2004 FDA Submission
12:00am
8-K
t0d2sye
21 May 04
Amylin Pharmaceuticals Announces Acceptance of 17 Abstracts for Publication at the American Diabetes Association Annual Meeting
12:00am
8-K
g381ymn ug
28 Apr 04
Financial statements and exhibits
12:00am
8-K
x8n6nw
6 Apr 04
Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers’ Option for Additional $25 Million of Convertible Senior Notes
12:00am
8-K
u9urmb989gb8b6p33e
1 Apr 04
Amylin Pharmaceuticals, Inc. Announces Pricing Of Convertible Senior Notes
12:00am
8-K
8crmy
31 Mar 04
Other events
12:00am
8-K
col3o
31 Mar 04
Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes
12:00am
8-K
w93he6te40ua9 7nn
24 Feb 04
Amylin Pharmaceuticals Reports 2003 Financial Results
12:00am
8-K
ebevclncfcvcx18z d7
13 Jan 04
Amylin Pharmaceuticals CEO to Provide Corporate Update at JPMorgan Healthcare Conference
12:00am
8-K
tkdfhrdkatiibxcc1
22 Dec 03
Amylin and Lilly Announce Achievement of First Exenatide Development Milestones
12:00am
8-K
db8odaz
18 Dec 03
Other events
12:00am
8-K
kjpqb9ca0j b9qx
25 Nov 03
Other events
12:00am
8-K
imn4rlhsefetj
12 Nov 03
Other events
12:00am